- Home
- AMLX vs INVA Comparison
AMLX vs INVA Comparison
Compare AMLX & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | INVA |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2022 | 2004 |
Fundamental Metrics
Financial Performance| Metric | AMLX | INVA |
|---|---|---|
| Price | $13.15 | $20.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $17.43 | ★ $36.60 |
| AVG Volume (30 Days) | ★ 1.2M | 756.1K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.96 |
| EPS | N/A | ★ 1.52 |
| Revenue | N/A | ★ $388,521,000.00 |
| Revenue This Year | N/A | $13.23 |
| Revenue Next Year | N/A | $8.62 |
| P/E Ratio | ★ N/A | $13.52 |
| Revenue Growth | N/A | ★ 10.14 |
| 52 Week Low | $2.60 | $16.52 |
| 52 Week High | $16.96 | $22.76 |
Technical Indicators
Market Signals| Indicator | AMLX | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 48.29 |
| Support Level | $12.69 | $20.45 |
| Resistance Level | $15.06 | $21.27 |
| Average True Range (ATR) | 0.76 | 0.53 |
| MACD | -0.16 | -0.20 |
| Stochastic Oscillator | 17.77 | 5.23 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.